Raphael Carandang to Treatment Outcome
This is a "connection" page, showing publications Raphael Carandang has written about Treatment Outcome.
Connection Strength
0.096
-
Carandang RA. Thirty Years After the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trial: A New Era for Stroke Therapy. JAMA Neurol. 2016 Mar; 73(3):265-7.
Score: 0.062
-
Silver B, Hamid T, Khan M, Di Napoli M, Behrouz R, Saposnik G, Sarafin JA, Martin S, Moonis M, Henninger N, Goddeau R, Jun-O'Connell A, Cutting SM, Saad A, Yaghi S, Hall W, Muehlschlegel S, Carandang R, Osgood M, Thompson BB, Fehnel CR, Wendell LC, Potter NS, Gilchrist JM, Barton B. 12 versus 24?h bed rest after acute ischemic stroke thrombolysis: a preliminary experience. J Neurol Sci. 2020 Feb 15; 409:116618.
Score: 0.020
-
Muehlschlegel S, Carandang R, Hall W, Kini N, Izzy S, Garland B, Ouillette C, van der Bom IM, Flood TF, Gounis MJ, Weaver JP, Barton B, Wakhloo AK. Dantrolene for cerebral vasospasm after subarachnoid haemorrhage: a randomised double blind placebo-controlled safety trial. J Neurol Neurosurg Psychiatry. 2015 Sep; 86(9):1029-35.
Score: 0.014